A Quiet Medicines Co. Raises Questions The Medicines Co.MDCO still seems to be playing by its own rules when it comes to making public disclosures about the regulatory status of its experimental hypertension drug Cleviprex.
At an investment conference last Thursday,...
A Quiet Medicines Co. Raises Questions The Medicines Co.MDCO still seems to be playing by its own rules when it comes to making public disclosures about the regulatory status of its experimental hypertension drug Cleviprex.
At an investment conference last Thursday,...
The Medicines Company Hires Glyn R. Parkin as Senior Vice President, International Operations The Medicines Company (NASDAQ: MDCO) today announced that Glyn R.Parkin has joined the Company as Senior Vice President, International Operations.
Working with other senior leaders of the Company, Parkin will be responsible for the...
The Medicines Company Receives FDA Review Letter for Angiomax Supplemental Filing - (NewsRx.com) -- (NASDAQ: MDCO) announced receipt of a not approvable letter from the U.S.Food and Drug Administration (FDA) on a supplemental New Drug Application (sNDA) for an additional dosing regimen for Angiomax(R) (bivalirudin) in...
The Medicines Company Receives FDA Review Letter for Angiomax Supplemental Filing - (NewsRx.com) -- (NASDAQ: MDCO) announced receipt of a not approvable letter from the U.S.Food and Drug Administration (FDA) on a supplemental New Drug Application (sNDA) for an additional dosing regimen for Angiomax(R) (bivalirudin) in...
Sepracor Completes Acquisition of Oryx Pharmaceuticals and Expands Operations in Canada MARLBOROUGH, Mass.--(HSMN NewsFeed)--Sepracor Inc.(Nasdaq: SEPR ) announced today that it has completed the acquisition of Oryx Pharmaceuticals Inc., an affiliate of the Arrow Group.
Oryx is a specialty pharmaceutical company that...
The Medicines Company to Participate in the Seventh Annual Needham & Company, LLC Biotechnology and Medical Te PARSIPPANY, N.J.--(BUSINESS WIRE)--The Medicines Company (NASDAQ: MDCO) is scheduled to present at The Seventh Annual Needham Biotechnology and Medical Technology Conference on June 12th, at 3:00pm Eastern Time.A company overview and...
Results Published in New England Journal of Medicine Show Angiomax Improved Net Clinical Outcomes and Resulted Results Published in New England Journal of Medicine Show Angiomax Improved Net Clinical Outcomes and Resulted in Improved Survival Rates in the Most Severe Heart Attack Patients 2008 JUN 9 - (NewsRx.com) -- The Medicines Company ...
The Medicines Company to Participate in the Seventh Annual Needham & Company, LLC Biotechnology and Medical Te PARSIPPANY, N.J.- (Business Wire) The Medicines Company (NASDAQ: MDCO) is scheduled to present at The Seventh Annual Needham Biotechnology and Medical Technology Conference on June 12th, at 3:00pm Eastern Time.
A company overview and...
::: Sepracor Completes Acquisition of Oryx Pharmaceuticals and Expands Operations in Canada MARLBOROUGH, Mass.--(BUSINESS WIRE)--Sepracor Inc.(Nasdaq: SEPR) announced today that it has completed the acquisition of Oryx Pharmaceuticals Inc., an affiliate of the Arrow Group.
Oryx is a specialty pharmaceutical company that...
Sepracor Completes Acquisition of Oryx Pharmaceuticals and Expands Operations in Canada MARLBOROUGH, Mass.--(BUSINESS WIRE)--Sepracor Inc.(Nasdaq: SEPR) announced today that it has completed the acquisition of Oryx Pharmaceuticals Inc., an affiliate of the Arrow Group.
Oryx is a specialty pharmaceutical company that...
Sepracor Completes Acquisition of Oryx Pharmaceuticals and Expands Operations in Canada , 7:00 AM EST News source: Business Wire Sepracor Inc.(Nasdaq: SEPR) announced today that it has completed the acquisition of Oryx Pharmaceuticals Inc., an affiliate of the Arrow Group.
Oryx is a specialty pharmaceutical company that...
Sepracor Completes Acquisition of Oryx Pharmaceuticals and Expands Operations in Canada MARLBOROUGH, Mass.- (Business Wire) Sepracor Inc.
(Nasdaq: SEPR) announced today that it has completed the acquisition of Oryx Pharmaceuticals Inc., an affiliate of the Arrow Group.
Oryx is a specialty pharmaceutical company that...
Sepracor Completes Acquisition of Oryx Pharmaceuticals and Expands Operations in Canada Company Website: http:www.sepracor.comMARLBOROUGH, Mass.-- (Business Wire) Sepracor Inc.
(Nasdaq: SEPR) announced today that it has completed the acquisition of Oryx Pharmaceuticals Inc., an affiliate of the Arrow Group.
Oryx is a...
Sepracor Completes Acquisition of Oryx Pharmaceuticals and Expands Operations in Canada MARLBOROUGH, Mass.--(BUSINESS WIRE)--Sepracor Inc.(Nasdaq: SEPR) announced today that it has completed the acquisition of Oryx Pharmaceuticals Inc., an affiliate of the Arrow Group.
Oryx is a specialty pharmaceutical company that...
The Medicines Company Receives FDA Review Letter For Angiomax Supplemental Filing Current Article Ratings: Patient / Public: Health Professional: Article Opinions: 0 posts (NASDAQ: MDCO) announced receipt of a not approvable letter from the U.S.Food and Drug Administration (FDA) on a supplemental New Drug Application ...
Medicines Company's heart drug not approvable: US FDA The Medicines Company announced receipt of a not approvable letter from the US Food and Drug Administration (FDA) on a supplemental New Drug Application (sNDA) for an additional dosing regimen for Angiomax (bivalirudin) in the...
The Medicines Company announces receipt of FDA review letter for Angiomax supplemental filing The Medicines Company (NASDAQ:MDCO), which is focused on advancing the treatment of critical care patients through the delivery of cost-effective medicines to the hospital marketplace, said on 28 May that the company has received a non...
US FDA rejects new Angiomax ACS use _ US FDA rejects new Angiomax ACS use.
The Medicines Company Receives FDA Review Letter for Angiomax Supplemental Filing - The Medicines Company (NASDAQ: MDCO) announced receipt of a not approvable letter from the U.S.Food and Drug Administration (FDA) on a supplemental New Drug Application (sNDA) for an additional dosing regimen for Angiomax(R) ...
Bivalirudin 'Nonapprovable' for ACUITY Indication from Heartwire - a professional news service of WebMD Sue Hughes May 28, 2008 The US FDA has issued a 'not approvable' letter to the Medicines Company for an additional dosing regimen for bivalirudin (Angiomax) in the upstream...
Medicines Company receives not approvable letter from FDA for Angiomax The Medicines Company has received a not approvable letter from the FDA on a supplemental new drug application for an additional dosing regimen for Angiomax in the treatment of acute coronary syndromes initiated in the emergency...
Cleviprex(TM) Reduces and Controls Acutely Elevated Blood Pressure in Elderly Patients, According to New Analy WASHINGTON--(BUSINESS WIRE)--The Medicines Company (NASDAQ: MDCO) today announced that its investigational agent, CleviprexTM (clevidipine butyrate) injectable emulsion was well tolerated in elderly patients and rapidly achieved and...
The Medicines Company Receives FDA Review Letter for Angiomax Supplemental Filing PARSIPPANY, N.J.--(HSMN NewsFeed)--The Medicines Company (NASDAQ: MDCO ) announced receipt of a not approvable letter from the U.S.Food and Drug Administration (FDA) on a supplemental New Drug Application (sNDA) for an additional dosing...
Angiomax Improves Outcomes in Heart Attack Patients - Angiomax (bivalirudin) significantly improved net clinical adverse events by 24 percent as well as resulted in a reduction in overall mortality by 32 percent and cardiac mortality by 38 percent when compared to heparin plus routine...
